Article ; Online: Midodrine reduces new-onset acute kidney injury and hyponatremia in children with cirrhosis and ascites awaiting liver transplantation: Results from an open-label RCT.
Journal of pediatric gastroenterology and nutrition
2023 Volume 78, Issue 2, Page(s) 350–359
Abstract: Objectives: Midodrine, an oral α-1-adrenergic receptor agonist, counters arterial hypovolemia and reduces complications in adult patients with cirrhosis. This randomized controlled trial (RCT) aimed to assess the efficacy and safety of midodrine in ... ...
| Abstract | Objectives: Midodrine, an oral α-1-adrenergic receptor agonist, counters arterial hypovolemia and reduces complications in adult patients with cirrhosis. This randomized controlled trial (RCT) aimed to assess the efficacy and safety of midodrine in preventing complications and improving survival in children with cirrhosis and ascites who are awaiting liver transplantation (LT). Methods: This open-label RCT conducted from January 2022 to May 2023 included children under 18 years with cirrhosis and ascites. Patients were randomized to receive either midodrine plus standard medical therapies (SMTs) or SMT alone. The primary outcome measure was the incidence of cirrhosis-related complications within 6 months. Results: Thirty-five subjects were enrolled and randomized. Patients in the midodrine arm had a lower incidence of new-onset acute kidney injury (AKI) compared with the SMT arm (11.1% vs. 41.2%). Patients in the midodrine arm showed a decline in serum creatinine and improvement in glomerular filtration rate, whereas no changes were observed in the SMT arm. There was a lower incidence of new-onset hyponatremia in the midodrine arm (20% vs. 56%). Midodrine led to reduction in plasma rennin activity (PRA) and improvement in systemic hemodynamics. There was no difference in the rate of resolution of ascites, recurrence of ascites, requirement of therapeutic paracentesis, cumulative albumin infusion requirement, episodes of spontaneous bacterial peritonitis, and hepatic encephalopathy between the two arms. Conclusion: Midodrine, when added to SMT, was effective in reducing the incidence of new-onset AKI and hyponatremia in pediatric cirrhotics awaiting LT. It also improved systemic hemodynamics and showed a trend towards reducing PRA. |
|---|---|
| MeSH term(s) | Adult ; Humans ; Child ; Adolescent ; Midodrine/therapeutic use ; Liver Transplantation/adverse effects ; Ascites/drug therapy ; Ascites/etiology ; Hyponatremia/complications ; Hyponatremia/drug therapy ; Treatment Outcome ; Liver Cirrhosis/complications ; Liver Cirrhosis/surgery ; Acute Kidney Injury/etiology ; Acute Kidney Injury/prevention & control |
| Chemical Substances | Midodrine (6YE7PBM15H) |
| Language | English |
| Publishing date | 2023-12-11 |
| Publishing country | United States |
| Document type | Randomized Controlled Trial ; Journal Article |
| ZDB-ID | 603201-1 |
| ISSN | 1536-4801 ; 0277-2116 |
| ISSN (online) | 1536-4801 |
| ISSN | 0277-2116 |
| DOI | 10.1002/jpn3.12077 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 1728: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.